BioRestorative Therapies Announces New Initiative to Target Polycystic Ovarian Syndrome

World News: . []

MELVILLE, N.Y., Sept. 11, 2019 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has expanded its “off-the-shelf” brown adipose derived stem cell therapeutic pipeline to target polycystic ovarian syndrome (PCOS). PCOS is the most common reproductive endocrine disease,  and can often lead to infertility, with up to 5 million patients in the United States. 

PCOS is difficult to manage and the current standard of care, including lifestyle changes and multi-line medications, may be moderately effective and unable to address long-term risks of type 2 diabetes, cardiovascular disease and psychiatric problems.

The Company hopes that its novel platform technology, using brown adipose derived stem cells, will become an emerging therapy for PCOS. The mechanisms of action involve both metabolic remodeling and endocrine secretions of the transplanted brown adipocytes that target both the PCOS metabolic symptoms as well as endocrine dysregulation. 

Collectively existing literature and the Company’s research and development supports transplanting metabolically active brown adipocytes (particularly with high level secretion of endocrine factors, such as adiponectin) to potentially improve or cure PCOS.

“Women’s health issues have been traditionally underserved,” said Mark Weinreb, CEO of BioRestorative Therapies. “And we are focusing on a potential therapeutic to address the needs of female patients who suffers from this prevalent disorder.”

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders. The production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using to treat persistent lower back pain due to painful degenerative discs.

• Metabolic Program (ThermoStem): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

CONTACT:Email: ir@biorestorative.com

More news and information about BioRestorative Therapies, Inc.

Published By:

Globe Newswire: 13:00 GMT Wednesday 11th September 2019

Published: .

Search for other references to "biorestorative" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us